Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal.; ICVS/3B's, PT Government Associate Laboratory, Braga, Guimarães, Portugal.; Stemmatters, Biotecnologia e Medicina Regenerativa SA - Parque de Ciência e Tecnologia AvePark, Zona Industrial da Gandra, 4805-017 Barco, Portugal.
Stemmatters, Biotecnologia e Medicina Regenerativa SA - Parque de Ciência e Tecnologia AvePark, Zona Industrial da Gandra, 4805-017 Barco, Portugal.
Biotechnol Adv. 2018 Jan-Feb;36(1):208-227. doi: 10.1016/j.biotechadv.2017.11.004. Epub 2017 Nov 15.
Integrins are cell adhesion receptors predominantly important during normal and tumor angiogenesis. A sequence present on several extracellular matrix proteins composed of Arg-Gly-Asp (RGD) has attracted attention due to its role in cell adhesion mediated by integrins. The development of ligands that can bind to integrins involved in tumor angiogenesis and brake disease progression has resulted in new investigational drug entities reaching the clinical trial phase in humans. The use of integrin-specific ligands can be useful for the vascularization of regenerative medicine constructs, which remains a major limitation for translation into clinical practice. In order to enhance vascularization, immobilization of integrin-specific RGD peptidomimetics within constructs is a recommended approach, due to their high specificity and selectivity towards certain desired integrins. This review endeavours to address the potential of peptidomimetic-coated biomaterials as vascular network promoters for regenerative medicine purposes. Clinical studies involving molecules tracking active integrins in cancer angiogenesis and reasons for their failure are also addressed.
整合素是细胞黏附受体，在正常和肿瘤血管生成中极为重要。由精氨酸-甘氨酸-天冬氨酸（RGD）组成的几种细胞外基质蛋白上存在的一个序列，由于其在整合素介导的细胞黏附中的作用而引起了关注。能够与肿瘤血管生成中涉及的整合素结合并阻止疾病进展的配体的开发，导致新的研究性药物实体进入人体临床试验阶段。整合素特异性配体的使用对于再生医学构建物的血管化可能是有用的，因为这仍然是转化为临床实践的主要限制。为了增强血管化，将整合素特异性 RGD 拟肽固定在构建物中是一种推荐的方法，因为它们对某些所需的整合素有很高的特异性和选择性。本综述旨在探讨拟肽涂层生物材料作为再生医学血管网络促进剂的潜力。还涉及涉及追踪癌症血管生成中活性整合素的分子的临床研究以及它们失败的原因。
